Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Hematology/Oncology ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2011-2015.Neuro Oncol. 2018; 20: iv1-iv86
- Patterns of care for adults with newly diagnosed malignant glioma.JAMA. 2005; 293: 557-564
- Seizures in low-grade gliomas: natural history, pathogenesis, and outcome after treatments.Neuro Oncol. 2012; 14: iv55-iv64
- The 2007 WHO classification of tumours of the central nervous system.Acta Neuropathol. 2007; 114: 97-109
- The 2016 World Health Organization classification of tumors of the central nervous system: a summary.Acta Neuropathol. 2016; 131: 803-820
- Effects of radiotherapy on cognitive function in patients with low-grade glioma measured by the folstein mini-mental state examination.J Clin Oncol. 2003; 21: 2519-2524
- Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study.J Clin Oncol. 2002; 20: 2267-2276
- Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial.Lancet. 2005; 366: 985-990
- Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802.J Clin Oncol. 2012; 30: 3065-3070
- Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma.N Engl J Med. 2016; 374: 1344-1355
- Phase 2 study of temozolomide-based chemoradiation therapy for high-risk low-grade gliomas: preliminary results of Radiation Therapy Oncology Group 0424.Int J Radiat Oncol Biol Phys. 2015; 91: 497-504
- Prognostic factors for survival in adult patients with cerebral low-grade glioma.J Clin Oncol. 2002; 20: 2076-2084
- Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951.J Clin Oncol. 2013; 31: 344-350
- Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study.Lancet. 2017; 390: 1645-1653
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.Lancet Oncol. 2009; 10: 459-466
- Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial.JAMA. 2017; 318: 2306-2316
- National Comprehensive cancer Network clinical practice guidelines in oncology: central nervous system cancers. 2016; Version 1.(Available at:) (Accessed October 29, 2016)
- Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial.J Clin Oncol. 2004; 22: 1583-1588
- International atomic energy agency randomized phase III study of radiation therapy in elderly and/or frail patients with newly diagnosed glioblastoma multiforme.J Clin Oncol. 2015; 33: 4145-4150
- NRG BN005 A Phase II Randomized Trial of Proton Vs. Photon Therapy (IMRT) for Cognitive Preservation in Patients With IDH Mutant, Low to Intermediate Grade Gliomas.(Available at:) (Accessed September 12, 2018)
- BN005: Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients With IDH Mutant Grade II or III Glioma.(Available at:) (Accessed April 30, 2019)
- BN001: dose-Escalated Photon IMRT or proton beam radiation therapy versus standard-dose radiation therapy and temozolomide in treating patients with newly diagnosed glioblastoma.(Available at:) (Accessed April 30, 2019)
- Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402.J Clin Oncol. 2013; 31: 337-343
- Epidemiology of intracranial meningioma.Neurosurgery. 2005; 57 ([discussion: 1088–5]): 1088-1095
- Ionizing radiation and the risk of brain and central nervous system tumors: a systematic review.Neuro Oncol. 2012; 14: 1316-1324
- Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma.Neuro Oncol. 2016; 18: 649-655
- Mitotic index is an independent predictor of recurrence-free survival in meningioma.Brain Pathol. 2015; 25: 266-275
- Anaplastic meningioma: an analysis of the National Cancer Database from 2004 to 2012.J Neurosurg. 2018; 128: 1684-1689
- Relevance of Simpson grading system and recurrence-free survival after surgery for World Health Organization Grade I meningioma.J Neurosurg. 2017; 126: 201-211
- TERT promoter mutations and risk of recurrence in meningioma.J Natl Cancer Inst. 2016; 108 (djv377)
- DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis.Lancet Oncol. 2017; 18: 682-694
- Intermediate-risk meningioma: initial outcomes from NRG Oncology RTOG 0539.J Neurosurg. 2018; 129: 35-47
- BN003: observation or radiation therapy in treating patients with newly diagnosed grade II meningioma that has been completely removed by surgery.(Available at:) (Accessed April 30, 2019)
- Stereotactic radiosurgery providing long-term tumor control of cavernous sinus meningiomas.J Neurosurg. 2002; 97: 65-72
- Radiosurgical treatment of cavernous sinus meningiomas: experience with 122 treated patients.Neurosurgery. 2002; 51 ([discussion: 1159–1]): 1153-1159
- Judicious resection and/or radiosurgery for parasagittal meningiomas: outcomes from a multicenter review. Gamma Knife Meningioma Study Group.Neurosurgery. 1998; 43 ([discussion: 413–4]): 405-413
- Single-fraction radiosurgery for presumed intracranial meningiomas: efficacy and complications from a 22-year experience.Int J Radiat Oncol Biol Phys. 2012; 83: 1414-1418
- Reirradiation of recurrent meningioma.J Clin Neurosci. 2012; 19: 1261-1264
- Chasing your dural tail: Factors predicting local tumor control after gamma knife stereotactic radiosurgery for benign intracranial meningiomas: In regard to DiBiase et al. (Int J Radiat Oncol Biol Phys 2004;60:1515-1519).Int J Radiat Oncol Biol Phys. 2005; 62 ([author reply: 618–9]): 616-618
- The palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group.Int J Radiat Oncol Biol Phys. 1980; 6: 1-9
- Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials.Int J Radiat Oncol Biol Phys. 1997; 37: 745-751
- Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases.J Clin Oncol. 2012; 30: 419-425
- Seizure prophylaxis in patients with brain tumors: a meta-analysis.Mayo Clin Proc. 2004; 79: 1489-1494
- Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC.3): a multicentre, randomised, controlled, phase 3 trial.Lancet Oncol. 2017; 18: 1049-1060
- Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial.Lancet Oncol. 2017; 18: 1040-1048
- Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05.Int J Radiat Oncol Biol Phys. 2000; 47: 291-298
- Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial.Neuro Oncol. 2013; 15: 1429-1437
- Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): a phase II multi-institutional trial.J Clin Oncol. 2014; 32: 3810-3816
- Preservation of neurocognitive function (NCF) with conformal avoidance of the hippocampus during whole-brain radiotherapy (HA-WBRT) for brain metastases: preliminary results of phase III trial NRG oncology CC001.Int J Radiat Oncol Biol Phys. 2018; 102: 1607
- Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study.Lancet Oncol. 2014; 15: 387-395
- Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma.Lung Cancer. 2013; 82: 282-287
- Management of brain metastases in tyrosine kinase inhibitor-naive epidermal growth factor receptor-mutant non-small-cell lung cancer: a retrospective multi-institutional analysis.J Clin Oncol. 2017; 35: 1070-1077
- Combined nivolumab and ipilimumab in melanoma metastatic to the brain.N Engl J Med. 2018; 379: 722-730
- Dabrafenib plus trametinib in patients with BRAF(V600)-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial.Lancet Oncol. 2017; 18: 863-873
Article info
Publication history
Published online: October 28, 2019
Footnotes
Disclosure: The authors have no disclosures related to this article.
Identification
Copyright
© 2019 Elsevier Inc. All rights reserved.
